Charles Schwab Investment Management Inc Pardes Biosciences, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$1.4 - $1.95 $79,056 - $110,114	-56,469 Reduced 74.59%	19,235 $34,000
Q4 2022 Feb 13, 2023	SELL	$0.85 - $1.69 $11,185 - $22,238	-13,159 Reduced 14.81%	75,704 $127,000
Q3 2022 Nov 14, 2022	SELL	$2.14 - $3.7 $247,724 - $428,308	-115,759 Reduced 56.57%	88,863 $165,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $8.57 $164,203 - $495,500	57,818 Added 39.38%	204,622 $629,000
Q1 2022 May 13, 2022	BUY	$5.64 - $15.64 $827,974 - $2.3 Million	146,804 New	146,804 $1.06 Million

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.